Company intelligence / Profile preview
Mucovax
Worcester, Massachusetts, United Statesmucovax.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Mucovax holds a proprietary mucosal vaccine platform originally developed at Biomere with $14.5 million in funding over 15 years. The company owns three patent families covering methods for tailoring immune responses, novel vaccination approaches for HSV2, and therapeutic vaccines for treating HSV2 infections. No published results from human clinical trials are available as of June 2025.
- Therapeutic areas
- Infectious Diseases
- Modalities
- VaccineRecombinant protein (via pichia expression system)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Crozet BioPharma is a key partner working with Mucovax to bring products based on the proprietary technology to market
Beyond the preview
Go deeper on Mucovax.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mucovax.